Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients

AIDS Research and Human Retroviruses

Volumn 24, Issue 7, 2008, Pages 1003-1007

  Xu, L ^a   Anderson, J ^b   Ferns, B ^c   Cook, P ^a   Wildfire, A ^d   Workman, J ^a   Graham, S ^a   Smit, E ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; INTEGRASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADULT; AMINO ACID SEQUENCE; FEMALE; GENES, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV-2; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ALIGNMENT; VARIATION (GENETICS);

EID: 48749125376     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0303     Document Type: Article

References (25)

1. de Bethune MP and Hertogs K: Screening and selecting for optimized antiretroviral drugs: Rising to the challenge of drug resistance 2. Curr Med Res Opin 2006;22(12):2603-2612.
2. Machouf N, Thomas R, Nguyen VK, et al.: Effects of drug resistance on viral load in patients failing antiretroviral therapy 1. J Med Virol 2006;78(5):608-613.
3. LaFemina RL, Schneider CL, Robbins HL, et al.: Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992;66(12):7414-7419.
4. Farnet CM and Haseltine WA: Integration of human immunodeficiency virus type 1 DNA in vitro. Proc Natl Acad Sci USA 1990;87(11):4164-4168.
5. Johnson AA, Marchand C, and Pommier Y: HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial. Curr Top Med Chem 2004;4(10):1059-1077.
6. O'Neal R: MK-0518 and GS-9137: Two promising integrase inhibitors in the pipeline. BETA 2006;18(4):13-16.
7. Grinsztejn B, Nguyen BY, Katlama C, et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007;369(9569):1261-1269.
8. Jones G, Ledford R, Yu F, et al.: Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Abstract 627 2007.
9. Cooper D, Gatell J, and Rockstroh J: Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with tripclass resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Abstract 105aLB 2007.
10. Steigbigel R, Kumer P, and Eron J: Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with tripclass resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Abstract 105bLB 2007.
11. Hazuda DJ, Miller MD, Nguyen BY, et al.: Resistance to the HIV-integrase inhibitor reltegravir: Analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection. Antiviral Ther 2007;12:S10. Abstract 8.
12. McColl DJ, Fransen S, Gupta S, et al.: Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase II study of elvitegravir (GS-9137). Antiviral Therapy 2007;12:S11. Abstract 9.
13. Rodes B, Holguin A, Soriano V, et al.: Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000;38(4):1370-1374.
14. Pieniazek D, Rayfield M, Hu DJ, et al.: HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004;18(3):495-502.
15. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006;14(3):125-130.
16. Reinke R, Steffen NR, and Robinson WE Jr: Natural selection results in conservation of HIV-1 integrase activity despite sequence variability. AIDS 2001;15(7):823-830.
17. Low A, Mohri H, Markowitz M, et al.: Frequency of naturally occurring polymorphisms associated with resistance to integrase inhibitors in a recently infected cohort. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Abstract 625 2007.
18. Passaes C, Guimaraes M, Lorete R, et al.: Genetic diversity of integrase in HIV-1 subtypes B, F, and C, prevalent in Brazil: Study in drug-naive and multi-drug-resistant individuals reveals impact for drug resistance. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Abstract 624 2007.
19. Zioni R, Thee S, Liu T, et al.: Natural variation of HIV-1 group M integrase: Implications for integrase inhibitor therapy. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Abstract 623 2007.
20. Myers RE and Pillay D: HIV-1 integrase sequence variation and covariation. Antiviral Ther 2007;12:S5. Abstract 5.
21. Xu L, Hue S, Taylor S, et al.: Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 2002;16(12):1684-1686.
22. Myers G, Foley B, Mellors JW, et al.: Human Retroviruses and AIDS 1996: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophasic Group, Los Alamos National Laboratory, Los Alamos, NM, 1996.
23. Bushman FD, Engelman A, Palmer I, Wingfield P, and Craigie R: Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci USA 1993;90(8):3428-3432.
24. van G, Groeneger AA, and Plasterk RH: Mutational analysis of the integrase protein of human immunodeficiency virus type 2. Proc Natl Acad Sci USA 1992;89(20):9598-9602.
25. Roquebert B, Damond F, Collin G, Matheron S, and Taieb A: Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors: Raltegravir and evitegravir. Antiviral Ther 2007;12:S92. Abstract 83.